NCT00856193View on ClinicalTrials.gov

A Study to Investigate the Bronchodilatory Effect of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Placebo

Matching placebo capsules were supplied for inhalation once daily with Concept 1 device.

DRUG

NVA237

NVA237 50 μg capsules were supplied for inhalation once daily with Concept 1 device.

Trial Locations (2)

29303

Spartanburg Medical Research, Spartanburg

80636

Harrison Clinical Research Deutschland GmbH, Albrechtstrasse 14

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00856193 - A Study to Investigate the Bronchodilatory Effect of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter | Biotech Hunter